Rare Heart Cancer Study Reveals Survival Patterns and Treatment Gaps

A new look at cardiac angiosarcoma, a rare and deadly heart cancer, shows how patient traits and treatment choices affect survival. Researchers pulled data from a major cancer registry covering 2001 to 2021.

They found 194 cases total. Most patients were 50 or younger. About 18% were Black. Sadly, 91% of patients died. The average survival was just 15 months. One-year survival was around 46%.

Tumor size mattered. Patients with tumors larger than 10 cm had worse outcomes. Higher-grade tumors also meant higher risk. Age played a role too. Patients aged 51 to 70 had different survival rates than younger or older groups.

Treatment made a big difference. Patients who did not get radiation therapy were more likely to die. Those who did not have surgery also faced higher death rates. Distant cancer spread was linked to worse survival.

Genetic studies found repeated mutations in genes like KDR, FLT4, PLCG1, and POT1. But most of these changes cannot be used for treatment yet. More research is needed to turn these findings into real therapies.